Prader-Willi Syndrome

Overview


Plain-Language Overview

Prader-Willi Syndrome is a rare genetic disorder that affects the brain and several body systems. It primarily impacts the hypothalamus, a part of the brain that controls hunger, growth, and hormone regulation. People with this condition often have a constant feeling of hunger, leading to overeating and obesity. Other common features include low muscle tone, delayed development, and learning difficulties. The syndrome also causes distinctive facial features and behavioral problems. Because it affects multiple systems, it requires careful medical monitoring throughout life.

Clinical Definition

Prader-Willi Syndrome is a complex genetic disorder caused by the loss of function of paternally expressed genes on chromosome 15q11-q13, most commonly due to a paternal deletion, maternal uniparental disomy, or imprinting defects. The core pathology involves hypothalamic dysfunction leading to hyperphagia, growth hormone deficiency, hypogonadism, and impaired temperature regulation. Clinically, it presents with neonatal hypotonia, feeding difficulties in infancy, followed by insatiable appetite and obesity in childhood. Additional features include intellectual disability, behavioral problems such as temper outbursts, and characteristic facial dysmorphisms. The syndrome is significant due to its lifelong impact on growth, metabolism, and neurodevelopment.

Inciting Event

  • Genetic abnormalities including paternal deletion, maternal uniparental disomy, or imprinting defects on chromosome 15q11-q13.

  • No environmental or infectious triggers are implicated in disease onset.

Latency Period

  • Symptoms typically begin in the neonatal period with hypotonia and poor feeding.

  • Hyperphagia and obesity develop gradually during early childhood, often by age 2 to 6 years.

  • Neurodevelopmental and behavioral symptoms become more apparent in early childhood.

Diagnostic Delay

  • Early hypotonia and feeding difficulties may be misattributed to non-specific neonatal conditions.

  • Lack of awareness of the syndrome’s progressive hyperphagia delays diagnosis until obesity develops.

  • Behavioral and cognitive symptoms may be mistaken for autism spectrum disorder or other neurodevelopmental disorders.

  • Genetic testing may be delayed due to limited access or low clinical suspicion.

Clinical Presentation


Signs & Symptoms

  • Neonatal hypotonia with poor suck and feeding difficulties

  • Hyperphagia leading to severe obesity in early childhood

  • Developmental delay and intellectual disability

  • Hypogonadism causing delayed or incomplete puberty

  • Behavioral problems including temper tantrums and obsessive-compulsive features

History of Present Illness

  • Neonatal history of severe hypotonia and poor suckling leading to feeding difficulties.

  • Progressive onset of hyperphagia with an insatiable appetite causing rapid weight gain in early childhood.

  • Development of mild to moderate intellectual disability and behavioral problems such as temper tantrums and obsessive-compulsive features.

  • Signs of hypogonadism including delayed or incomplete puberty.

  • Sleep disturbances and excessive daytime sleepiness are common.

Past Medical History

  • History of neonatal hypotonia and failure to thrive despite adequate feeding.

  • Previous episodes of respiratory infections due to hypotonia-related complications.

  • No prior significant medical conditions unrelated to the syndrome.

Family History

  • Usually sporadic cases with no family history due to de novo genetic events.

  • Rare familial cases may occur due to inherited imprinting center defects.

  • No consistent association with other inherited syndromes.

Physical Exam Findings

  • Hypotonia with decreased muscle tone in infancy

  • Short stature and small hands and feet

  • Almond-shaped eyes and narrow bifrontal diameter

  • Obesity developing in early childhood due to hyperphagia

  • Cryptorchidism in males

  • Thin upper lip and downturned mouth

Diagnostic Workup


Diagnostic Criteria

Diagnosis is established by clinical suspicion based on hallmark features including hypotonia, feeding difficulties in infancy, followed by hyperphagia and obesity, developmental delay, and characteristic facial features. Confirmation requires genetic testing demonstrating abnormalities in the 15q11-q13 region, such as paternal deletion, maternal uniparental disomy, or imprinting defects. Methylation analysis is the preferred initial test as it detects all major genetic causes. Additional tests may include fluorescence in situ hybridization (FISH) or chromosomal microarray to identify deletions.

Pathophysiology


Key Mechanisms

  • Loss of paternal expression of imprinted genes on chromosome 15q11-q13 leads to hypothalamic dysfunction.

  • Hypothalamic dysfunction causes impaired satiety regulation resulting in hyperphagia and obesity.

  • Deficient secretion of growth hormone and other pituitary hormones contributes to short stature and hypogonadism.

  • Abnormalities in neurodevelopmental pathways cause intellectual disability and behavioral problems.

  • Impaired autonomic regulation leads to temperature instability and reduced pain sensitivity.

InvolvementDetails
Organs

Hypothalamus is critically involved due to genetic abnormalities causing impaired appetite regulation and endocrine dysfunction.

Pituitary gland dysfunction leads to growth hormone deficiency and other hormonal imbalances.

Brain abnormalities contribute to intellectual disability and behavioral problems.

Tissues

Adipose tissue is increased due to hyperphagia and decreased energy expenditure, leading to obesity.

Muscle tissue is hypotonic and underdeveloped, contributing to motor delays and weakness.

Cells

Hypothalamic neurons are dysfunctional, leading to impaired satiety signaling and endocrine abnormalities in Prader-Willi syndrome.

Chemical Mediators

Ghrelin levels are elevated, contributing to hyperphagia and obesity in Prader-Willi syndrome.

Growth hormone deficiency is common and contributes to short stature and abnormal body composition.

Treatments


Pharmacological Treatments

  • Growth hormone

    • Mechanism:
      • Stimulates linear growth and improves body composition by increasing muscle mass and decreasing fat mass.

    • Side effects:
      • Edema

      • Joint pain

      • Increased intracranial pressure

    • Clinical role:
      • First-line

  • Psychotropic medications

    • Mechanism:
      • Modulate neurotransmitter systems to manage behavioral problems such as temper outbursts and obsessive-compulsive features.

    • Side effects:
      • Sedation

      • Weight gain

      • Extrapyramidal symptoms

    • Clinical role:
      • Adjunctive

Non-pharmacological Treatments

  • Strict environmental control with supervised access to food to prevent hyperphagia and obesity.

  • Behavioral therapy to address temper tantrums, compulsive behaviors, and improve social skills.

  • Nutritional counseling to maintain a balanced, calorie-restricted diet.

  • Physical therapy to improve hypotonia and motor development.

  • Early developmental interventions including speech and occupational therapy.

Prevention


Pharmacological Prevention

  • Growth hormone therapy to improve body composition and height

  • Metformin to manage insulin resistance and prevent diabetes

  • Melatonin for sleep disturbances

  • Psychotropic medications for behavioral and psychiatric symptoms

  • Hormone replacement therapy for hypogonadism

Non-pharmacological Prevention

  • Strict dietary supervision to prevent hyperphagia and obesity

  • Regular physical activity to improve muscle tone and metabolic health

  • Early developmental interventions including physical and occupational therapy

  • Behavioral therapy to manage compulsive behaviors

  • Sleep studies and respiratory support to prevent apnea complications

Outcome & Complications


Complications

  • Severe obesity-related complications including cardiovascular disease

  • Respiratory failure from obstructive sleep apnea

  • Type 2 diabetes mellitus with associated microvascular and macrovascular damage

  • Gastric rupture due to uncontrolled hyperphagia

  • Hypoventilation syndrome from central and peripheral respiratory control abnormalities

Short-term Sequelae Long-term Sequelae
  • Feeding difficulties and failure to thrive in infancy

  • Hypotonia-related respiratory insufficiency

  • Early onset obesity with rapid weight gain

  • Delayed motor milestones

  • Behavioral outbursts complicating care

  • Morbid obesity with metabolic syndrome

  • Intellectual disability with lifelong cognitive impairment

  • Hypogonadism-related infertility

  • Scoliosis and orthopedic deformities

  • Psychiatric illness requiring ongoing management

Differential Diagnoses


Prader-Willi Syndrome versus Angelman Syndrome

Prader-Willi Syndrome

Angelman Syndrome

Paternal deletion or uniparental disomy of chromosome 15q11-q13

Maternal deletion or mutation of chromosome 15q11-q13

Loss of expression of paternally imprinted genes in 15q11-q13 region

UBE3A gene mutation or deletion

Mild to moderate intellectual disability with hyperphagia and hypotonia

Severe intellectual disability with frequent laughter and ataxia

Methylation analysis showing loss of paternal allele

Methylation analysis showing loss of maternal allele

Prader-Willi Syndrome versus Bardet-Biedl Syndrome

Prader-Willi Syndrome

Bardet-Biedl Syndrome

Usually sporadic with imprinting defects or uniparental disomy

Autosomal recessive inheritance

Abnormal methylation or deletion on chromosome 15q11-q13

No specific methylation abnormalities on chromosome 15

Neonatal hypotonia and early childhood hyperphagia without polydactyly

Progressive retinal dystrophy and polydactyly

Methylation studies or FISH showing 15q11-q13 abnormalities

Genetic testing showing mutations in BBS genes

Prader-Willi Syndrome versus Down Syndrome

Prader-Willi Syndrome

Down Syndrome

Imprinting or deletion abnormalities on chromosome 15

Trisomy 21 due to nondisjunction

Normal karyotype with methylation defects on chromosome 15

Karyotype showing trisomy 21

Hypotonia and hyperphagia without typical Down syndrome facies

Characteristic facial features and congenital heart defects

Methylation or FISH confirming 15q11-q13 deletion or uniparental disomy

Chromosomal analysis confirming trisomy 21

Prader-Willi Syndrome versus Hypothalamic Obesity

Prader-Willi Syndrome

Hypothalamic Obesity

No history of hypothalamic damage; genetic cause

History of hypothalamic injury or tumor

Progressive obesity starting in early childhood with developmental delay

Rapid onset obesity after hypothalamic insult

Abnormal methylation or deletion on chromosome 15q11-q13

Normal genetic testing; obesity secondary to hypothalamic dysfunction

Prader-Willi Syndrome versus Fragile X Syndrome

Prader-Willi Syndrome

Fragile X Syndrome

Imprinting defect or deletion on chromosome 15q11-q13

X-linked dominant inheritance with CGG repeat expansion in FMR1 gene

Hypotonia, hyperphagia, and mild to moderate intellectual disability

Intellectual disability with prominent behavioral features and macroorchidism

Methylation studies or FISH showing abnormalities in 15q11-q13

PCR showing CGG repeat expansion in FMR1 gene

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.